Clorox
CLX
$98.30
-1.03%
The Clorox Company is a leading consumer goods manufacturer operating in the Household & Personal Products industry, with a diversified portfolio spanning cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water filtration, and natural personal care under iconic brands like Clorox, Pine-Sol, Glad, Hidden Valley, Brita, and Burt's Bees. It is a dominant market player in several of its categories, particularly in the U.S. where over 80% of sales are generated, leveraging strong brand equity and a century-old heritage. The current investor narrative is intensely focused on the company's challenging turnaround story, as recent financial performance has been pressured, leading the stock to multi-year lows and sparking debate between its status as a high-yield 'dividend aristocrat' contrarian opportunity versus a value trap facing significant operational headwinds.…
CLX
Clorox
$98.30
Related headlines
Investment Opinion: Should I buy CLX Today?
Rating: Hold. The core thesis is that CLX is a deeply challenged but not broken company trading at a valuation that largely reflects its problems, making it a high-risk, speculative turnaround story rather than a compelling buy.
Supporting evidence includes a forward PE of 14.24x, which is not demanding for a staple company, and a high 4.06% dividend yield that provides compensation for waiting. However, revenue growth is absent (-0.77% YoY), profitability is under pressure (net margin of 9.38% vs. TTM 11.4%), and the balance sheet is over-leveraged (D/E 8.97). Analyst consensus is neutral-to-bearish, with no clear price target upside to anchor a bullish view.
The two biggest risks are 1) further margin compression making the dividend unsustainable, and 2) an inability to reduce debt, leading to a credit rating downgrade. This Hold would upgrade to a Buy only if quarterly revenue shows sustained positive growth and gross margins stabilize above 44% for two consecutive quarters, signaling a turnaround is underway. It would downgrade to a Sell if free cash flow coverage of the dividend deteriorates or the stock breaks decisively below its 52-week low of $84.7. Relative to its own battered history and challenged fundamentals, the stock is fairly valued—the market is not paying a premium for growth it doesn't have, but it is also not pricing in a total collapse, given the brand value and cash flow.
Sign up to view all
CLX 12-Month Price Forecast
CLX is in a painful transition, with its high yield and depressed valuation offering compensation for significant operational and financial risk. The base case of sideways movement is most likely, as turning around a leveraged consumer staples giant is a multi-year process. The AI stance is Neutral due to the balanced risk/reward; the high yield offsets the lack of growth, but the leverage prevents a bullish call. The stance would upgrade to Bullish on concrete evidence of margin recovery and debt reduction, or downgrade to Bearish on a breakdown of the $84.7 support level, which would signal the value trap narrative is winning.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Clorox's 12-month outlook, with a consensus price target around $127.79 and implied upside of +30.0% versus the current price.
Average Target
$127.79
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$79 - $128
Analyst target range
Analyst coverage is limited, with only 5 analysts providing estimates, indicating this large-cap stock has subdued institutional research interest, which can contribute to higher volatility and less efficient price discovery. The consensus sentiment leans neutral to bearish, as evidenced by recent institutional ratings which are predominantly 'Hold', 'Neutral', 'Equal Weight', or 'Underperform' from firms like Deutsche Bank, Morgan Stanley, Evercore ISI, UBS, and JP Morgan, with no recent 'Buy' upgrades noted in the provided data. Without explicit price targets provided in the dataset, the implied upside or downside cannot be calculated; however, the wide dispersion in historical valuation metrics and the stock's significant decline suggest analyst views are likely cautious, with a high target potentially assuming a successful margin recovery and debt reduction, while a low target would price in further market share erosion and dividend risk.
Bulls vs Bears: CLX Investment Factors
The evidence currently tilts bearish, as the company's severe operational headwinds—stagnant revenue, margin pressure, and extreme leverage—are concrete and ongoing, outweighing the potential value offered by its depressed price and high yield. The bull case rests almost entirely on a successful multi-year turnaround that has yet to materialize. The single most important tension in the investment debate is whether CLX's powerful brand equity and cash flow can overcome its crippling debt load to execute a margin recovery before further market share erosion. If management can stabilize margins and demonstrate a credible debt reduction plan, the stock could re-rate significantly; if not, the high dividend yield may prove unsustainable, leading to further price declines.
Bullish
- Deeply Oversold, Near 52-Week Low: The stock trades at $89.63, just 5.8% above its 52-week low of $84.7, after a 30.9% decline over the past year. This extreme price compression, coupled with a forward PE of 14.2x, suggests most negative news is priced in, creating a potential value entry point for contrarian investors.
- High Dividend Yield of 4.06%: The stock offers a compelling 4.06% dividend yield, significantly above typical consumer staples yields, supported by a 74% payout ratio. The company's recent declaration of a $1.24 quarterly dividend reinforces its 'Dividend Aristocrat' status, providing income support while investors await a turnaround.
- Strong Free Cash Flow Generation: Despite operational challenges, CLX generated $778M in TTM free cash flow and $269M in the latest quarter. This robust cash generation provides a critical cushion to service its high debt, fund the dividend, and invest in its business, mitigating near-term liquidity risks.
- Valuation Compression to Historical Lows: The trailing PE has collapsed from a recent high of 47.25x to 18.31x, a 61% de-rating. The forward PE of 14.24x implies the market expects minimal growth, positioning the stock at the lower end of its historical valuation range and offering limited downside if fundamentals stabilize.
Bearish
- Severe Financial Leverage (D/E of 8.97): A debt-to-equity ratio of 8.97 indicates a highly leveraged capital structure that amplifies financial risk. This constrains strategic flexibility, increases interest expense ($28M last quarter), and raises concerns about dividend sustainability during prolonged downturns.
- Stagnant/Declining Revenue Growth: Latest quarterly revenue of $1.673B declined -0.77% YoY, with revenue fluctuating without a clear growth path over recent quarters. This top-line stagnation in a competitive environment challenges the core investment thesis of a stable, growing consumer staples business.
- Profitability Under Significant Pressure: Gross margin of 43.16% in the latest quarter is below the TTM gross margin of 45.2%, and net margin of 9.38% is below the TTM net margin of 11.4%. This indicates persistent inflationary cost pressures and competitive pricing are eroding earnings power.
- Extreme Relative Underperformance: CLX has underperformed the SPY by -57.9% over the past year, a catastrophic level of idiosyncratic weakness. This severe underperformance signals a fundamental breakdown in investor confidence that may not reverse quickly, even if the broader market rallies.
CLX Technical Analysis
The prevailing price trend is a pronounced and sustained downtrend, with the stock down 30.87% over the past year and trading near the bottom of its 52-week range. With a current price of $89.63, it sits just 12% above its 52-week low of $84.7 and 32% below its 52-week high of $132.03, indicating the stock is deeply oversold and in a bearish phase, presenting a potential value opportunity but also signaling significant negative momentum and investor pessimism. Recent short-term momentum shows a modest 4.08% gain over the past month, which diverges from the severe longer-term downtrend, potentially signaling a tentative stabilization or a dead-cat bounce; however, this is overshadowed by a steep 21.83% decline over the past three months, confirming that selling pressure has been intense and any recent uptick lacks conviction. Key technical levels are clearly defined, with immediate support at the 52-week low of $84.7 and major resistance at the 52-week high of $132.03; a breakdown below $84.7 would likely trigger further capitulation, while a sustained move above this recent low-trading range is needed to suggest a base is forming. The stock's beta of 0.575 indicates it is 42.5% less volatile than the broader market (SPY), which is typical for a defensive consumer staples name but has not shielded it from severe idiosyncratic underperformance, as evidenced by its massive -57.91% relative strength versus the SPY over the past year.
Beta
0.55
0.55x market volatility
Max Drawdown
-37.6%
Largest decline past year
52-Week Range
$85-$132
Price range past year
Annual Return
-22.1%
Cumulative gain past year
| Period | CLX Return | S&P 500 |
|---|---|---|
| 1m | +10.3% | -0.1% |
| 3m | -11.2% | +11.4% |
| 6m | -5.5% | +8.2% |
| 1y | -22.1% | +22.7% |
| ytd | -2.5% | +8.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CLX Fundamental Analysis
The company's revenue trajectory is stagnant to slightly negative, with the most recent quarterly revenue of $1.673 billion representing a -0.77% year-over-year decline; examining the multi-quarter trend, revenue has fluctuated between $1.429 billion and $1.988 billion without a clear growth path, indicating the business is struggling to achieve top-line expansion in a competitive environment. Profitability is present but under pressure, with net income of $157 million in the latest quarter and a gross margin of 43.16%; however, gross margin has been volatile, ranging from 41.57% to 46.33% over recent quarters, and the net margin of 9.38% is below the trailing twelve-month net margin of 11.40%, suggesting inflationary costs and competitive pressures are compressing earnings. The balance sheet shows significant financial leverage with a debt-to-equity ratio of 8.97, indicating a highly leveraged capital structure that amplifies risk; however, the company generated $311 million in operating cash flow and $269 million in free cash flow in the latest quarter, and its trailing twelve-month free cash flow of $778 million provides a solid cushion to service debt and maintain its dividend, though the current ratio of 0.84 points to potential near-term liquidity constraints.
Quarterly Revenue
$1.7B
2025-12
Revenue YoY Growth
+0.00%
YoY Comparison
Gross Margin
+0.43%
Latest Quarter
Free Cash Flow
$778000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CLX Overvalued?
Given that Net Income is positive ($157M in the latest quarter), the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 18.31x and a forward PE of 14.24x; the forward multiple being 22% lower than the trailing multiple implies the market expects earnings growth or recovery in the coming year, though this expectation is tempered by the company's recent challenges. Compared to sector averages, the trailing PE of 18.31x is not directly comparable without a provided industry average, but the Price-to-Sales (PS) ratio of 2.09x and EV/EBITDA of 12.67x offer alternative cross-checks; the dividend yield of 4.06% is notably high for a consumer staples company, reflecting the stock's price decline and market skepticism about the sustainability of its payout amidst its leveraged balance sheet. Historically, the stock's own valuation has compressed dramatically from its recent past; for instance, its PE ratio was as high as 47.25x in Q1 2026 and has since fallen to 18.31x, indicating the market has significantly de-rated the stock due to deteriorating fundamentals, placing it near the lower end of its own historical valuation range, which could signal a value opportunity if the turnaround materializes.
PE
18.3x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -98x~185x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are elevated and center on the company's highly leveraged balance sheet. With a Debt-to-Equity ratio of 8.97, CLX's financial structure is precarious, amplifying the impact of any earnings miss. Revenue stagnation, evidenced by a -0.77% YoY decline last quarter, combined with volatile gross margins (ranging from 41.6% to 46.3% recently), creates uncertainty around core profitability. The current ratio of 0.84 signals potential liquidity strain, though substantial TTM free cash flow of $778M provides a near-term buffer for its dividend and interest obligations.
Market & Competitive Risks include valuation compression and severe loss of investor favor. The stock's trailing PE has collapsed from 47.25x to 18.31x, a massive de-rating that may not be over if earnings continue to disappoint. Its catastrophic -57.9% relative strength versus the SPY over the past year indicates it is being treated as a value trap, not a defensive staple. Competitive pressures from private label and larger peers in its core cleaning and household categories threaten pricing power and market share, hindering any top-line recovery.
Worst-Case Scenario involves a continuation of operational missteps leading to a dividend cut. A chain of events where inflation persists, market share erodes further, and a recession hits consumer spending could force FCF below the level needed to cover the dividend and debt service. This would break the 'Dividend Aristocrat' narrative, triggering a final wave of selling. The realistic downside in this adverse scenario is a break below the 52-week low of $84.7, potentially testing levels 20-25% lower from the current price, representing a total loss from current levels of approximately -30% to -35%.
FAQ
The key risks, in order of severity, are: 1) Financial Risk: Extreme leverage with a Debt-to-Equity ratio of 8.97, which could threaten the dividend if earnings decline. 2) Operational Risk: Stagnant revenue (-0.77% YoY) and pressured profitability, with net margin falling to 9.38%. 3) Competitive/Market Risk: Loss of market share to private label and peers, evidenced by catastrophic -57.9% relative underperformance vs. the SPY. 4) Sentiment Risk: The stock is perceived as a value trap, with neutral-to-bearish analyst ratings, which can lead to prolonged underperformance even if fundamentals stop deteriorating.
The 12-month forecast presents three scenarios. The Base Case (50% probability) sees the stock trading between $90 and $110 as the company muddles through with flat sales, stable but pressured margins, and a maintained dividend. The Bull Case (25% probability) targets $115 to $132 on successful margin recovery and debt reduction initiatives. The Bear Case (25% probability) warns of a drop to $75-$85 if operational deterioration forces a dividend cut or credit downgrade. The Base Case is most likely, implying limited near-term upside but a high yield while investors wait for a potential longer-term turnaround.
CLX appears fairly valued relative to its current challenged fundamentals. Its forward PE of 14.24x is not expensive and reflects low growth expectations. However, compared to its own history—where its PE was above 47x just a few quarters ago—it looks cheap. This compression signals the market has severely de-rated the stock due to operational issues. The valuation implies the market expects stagnant growth and continued margin pressure, but not a catastrophic failure, given the brand portfolio and cash flow. It is not undervalued enough to ignore the risks, nor overvalued given the high yield cushion.
CLX is a high-risk, potentially high-reward contrarian buy, not a core portfolio holding. It could be a good buy for a specific investor profile: a patient, income-focused contrarian willing to accept significant fundamental risk for a 4.06% yield and the chance of a multi-year turnaround. The stock is deeply oversold, but the severe -30.9% annual decline and high debt load (D/E 8.97) mean the downside risk to the 52-week low of $84.7 (a -6% move) and below is real. It is not a good buy for growth investors or those seeking low-volatility stability.
CLX is strictly a long-term, patient investment, unsuitable for short-term trading. The turnaround required to justify a higher valuation is a multi-year process. Its low beta of 0.575 reduces day-to-day volatility but hasn't prevented a severe downtrend, making short-term timing exceptionally difficult. The 4.06% dividend yield is a key component of the total return thesis, which benefits from compounding over time. Investors should have a minimum horizon of 3-5 years to allow management time to execute its strategy and for the market to re-assess the story. There are no clear short-term catalysts for a sharp rally.